A particular drug, known as TGR-1202 (umbralisib), has been awarded a grant to support its development from the National Multiple Sclerosis Society. If you are wondering what exactly is MS and why does it affect a person’s way of life, you can head over here to find out more about this condition.
Grant awarded to a potentially novel Multiple Sclerosis drug
Essentially, the TGR-1202 is apparently a novel PI3K-delta inhibitor which is structured as an orally ingested medication designed to combat against the various progressive forms of Multiple Sclerosis. Competing against other potential drugs, the TGR was selected in a highly competitive process. According to the “Sponsor Research Agreement”, Fast Forward (a non-profit subsidiary of National Multiple Sclerosis Society) will provide funds to support the research and development in TGR’s preclinical process. Lawrence Steinman, MD, from Stanford University will be taking charge and leading the research process.
It seems that one of the reasons why the drug has been approved is the fact that it took on a B-cell targeted therapy. B-cell targeted therapy has been a recent treatment method that has proven attractive for patients suffering from progressive and relapsing MS. The recent clinical approval of ocrelizumab in March by FDA proved this point.
What is the catch here?
Basically, many proof of concepts for various diseases are constantly being ran. However, sometimes (rarely but it does happen), some drugs potentially become blockbuster drugs or truly are able to help people suffering from chronic conditions and incurable diseases after getting the assistance they need from certain societies and foundations to push through the massive capital outlay involved in the development of a drug.
TG Therapeutics, the company which received the funding will definitely be one to watch for in the next few years. We do hope that they can come up with a novel treatment, as many patients of MS can stand to benefit if they do.